

25
years of

**Nurturing,
Enriching and
Caring for life**



Celebrating Silver Jubilee of Operations

Nectar Lifesciences Ltd | ANNUAL REPORT 2021-22

Contents



About the Company	02
Our 25-year Journey	06
From the Chairman's desk	08
From CEO's desk	10
Management Discussion and Analysis	12
Board of Directors' Report	21
Report on Corporate Governance	27
Business Responsibility Report	43
Standalone Financial statements	57
Consolidated Financial statements	88
Notice	118

We turned 25!

Zealous in our Mind, Gutsy on our feet,

We're excited to have passed hurdles and to achieve this feat!

Rich in experience and Young in energy,

Our Silver lining has been our People-Quality-Processes and their Synergy!

We're at this age where everything is achievable in our spirit & sight,

We're at that milestone from where the horizon is Bright.

**It's simply
fantastic
to be 25**

And we're enjoying it.

About the Company

A global leader in the cephalosporin space.

A Company that emerged as a top ranked organisation amongst mid-sized Pharmaceutical companies in India.*

**We are
Just 25!**

**As per "Fortune Next 500" 2022*

Nectar Lifesciences Ltd. is a knowledge driven organisation which constitutes a vital part of fast growing Indian Pharmaceutical industry. The company has global leadership

in several oral and sterile cephalosporin drugs, and has cGMP facilities along with those approved by the European Union and Japan.

The Company enjoys a strong


presence in almost 64 countries of the world, with 13 state of Art API manufacturing facilities spread across the States of Punjab and Himachal Pradesh with compliance to

global standards of cGMP, Environment Health Safety (EHS) as well as pool of thousands of highly skilled, knowledgeable, competent qualified work force at all levels.

Our global certifications



Our global presence



Our business verticals

Active Pharmaceutical Ingredients (APIs)

Nectar has two manufacturing units with 13 facilities. The Plant has a total oral and sterile capacity of more than 2000 MT.

All its facilities can be converted to multi-purpose plants based on product basket requirement.

Nectar is the world's leading producer of Cefixime Trihydrate, Cefuroxime Axetil, Cefpodoxime Proxetil and Sterile APIs.

Formulations

Nectar's facility over 5 acres in Baddi is operated with minimum human intervention.

Our product basket includes Tablets (180 mn per year), Capsules (180 mn per year), Injectable Vials (240 mn per year) and Oral Suspension (10.5 mn per year).

Have a strong compliance and quality which leads to highest quality products that conform to stringent regulatory guidelines of various authorities such as USFDA, EDQM, MHRA, MCC, PMDA etc.

Currently cater to high-end RoW markets.

Major breakthrough by filing two major cephalosporin formulations in Europe, soon to be followed by 10 additional MAs.



Our key numbers

13

APIs Manufacturing facilities.

1

Formulations Manufacturing facility.

1

Empty hard gelatine capsule Manufacturing facility.

3

Phytochemical (Menthol) Manufacturing facilities

1

Guar Gum Manufacturing facility.*

1,669

Team size (March 31, 2022)

* un-operational as of now



Regulatory Filings

44

Approved DMFs

10

CEPs

170

EBITDA (₹ Crore)

25.32

Profit after Tax (₹ Crore)

1,086.86

Net worth (₹ Crore)

Our 25-year journey

1997

Nectar Lifesciences started business operations

2006

Issue of Foreign Currency Convertible Bonds (FCCBs) and listing thereof on Singapore Stock Exchange.

400,000 sq. meter API Manufacturing Unit II was inaugurated

2010

Issue of Private Equity to Foreign Investor

Issue of Global Depository Receipts (GDRs) and listing thereof on Luxembourg Stock Exchange.

2005

Initial Public Issue and listing on BSE and NSE

2007

Formulation manufacturing Unit 6 was inaugurated

EHGC Manufacturing Unit 7 was inaugurated

2011

Repayment of FCCBs

USFDA, EUGMP, PMDA, KFDA approvals attained

Collaboration with an innovator company.

Received an Award of Honour by APCON

2013

ANDA Filings initiated

2015

National Energy conservation award (NECA)- Runners Up!

44 DMFs across the globe

ANVISA approval to API Unit 2

2019

Bagged Outstanding export performance by Pharmexcil

2022

Bagged Best Preferred Supplier in Total Quality Achievement by a Leading MNC for third year in a row

Ranked 119 in Fortune India Next 500 Most Emerging Company

2014

Received Best Strategic Partner Award from an US MNC

2018

Ranked No1 mid-sized drugs & pharma company by "Fortune Next 500"

Bagged National Energy conservation award (NECA)

2021

Bagged Best Strategic partner Award from global suppliers.



From the Chairman's desk

With the worst behind us, we are particularly energised for a riveting journey ahead.

Dear shareholders,

It is an absolute pleasure to be sharing my thoughts with you at a time when the Company's fortunes turned around – from a negative bottom line of ₹73.14 Crore in FY21 to the positive zone with a Net Profit of ₹25.32 Crore in FY22. The swing of nearly ₹100 Crore was owing to a combination of two factors – a 9% increase in the topline and numerous small yet meaningful initiatives that pruned costs to sales by about 6%.

What make this turnaround special is that it has come at a time when the Company successfully completes 25 years of its exciting business journey. I take this opportunity to express my wholehearted gratitude to the entire team who have been with Nectar along this journey. The contribution of every individual along the way, has helped in uplifting the Company to a global position of respect and recognition.

Having come this far, the lingering question is how we would sustain this momentum going forward-a pertinent thought, especially after four years of subdued performance. I remain pragmatic about the future as I can see green shoots of opportunity over the horizon.

The Covid-19 pandemic, while brutally impacting lives, has made one-and-all extremely health-conscious. As such, the consumption of medicine, protective and curative, has seen a considerable jump in recent times. This trend will continue for some time until we get back to our undisciplined days, yet again. It augurs well for the entire pharmaceutical sector.

Coming to our therapy that is anti-infective, the future appears inspiring. Credible estimates suggest that the global anti-infective drugs market is expected to increase from US\$116.4 billion in 2021 to US\$158.29 billion in 2025 at a CAGR of 8%¹. Moreover, the consumption of high-end cephalosporin both orals and injectable,